虞美医药科技有限公司

    Yumed Pharmaceutical Technology Co.,Ltd

  • 0512-65116385

  • info@yumed.com.cn

yumed Pharmaceutical CDMO Project Signed for New Materials Industrial Park in Haiyu Town, Changshu City

October 15, 2021

Changshu Haiyu Town (New Materials Industrial Park) 2021 Industrial Project

Centralized signing ceremony

Held at Changshu Convention Center

WeChat Images_20230302160847. jpg

Wan Xiaojun, Vice Mayor of Changshu City; Changshu Development and Reform Commission, Changshu Industry and Information Technology Bureau, Changshu Commerce Bureau, Changshu Natural Resources and Planning Bureau, Changshu Market Supervision and Administration Bureau, Changshu Emergency Management Bureau, Suzhou Changshu Ecological Environment Bureau, Changshu Administrative Approval Bureau, and other relevant leaders in charge; Zhu Huiming, Secretary of the Party Committee of Haiyu Town and Secretary of the Party Working Committee of the New Materials Industrial Park, Xu Yajun, Deputy Secretary of the Party Committee and Mayor of Haiyu Town, Jin Yongqing, Deputy Secretary of the Party Working Committee and Director of the Management Committee of the New Materials Industrial Park, and relevant leaders and department heads in charge of the economic port of Haiyu Town (New Materials Industrial Park); Representatives of signed projects such as Huayi Sanaifu, Akema Fluorochemical, Dajin Fluorochemical, Xintai New Materials, and Kangyu Life Sciences attended the signing ceremony.

c4f3c9304aeb93ceec38015e5869b31c.jpg

At the meeting, Jin Yongqing, Deputy Secretary of the Party Working Committee and Director of the Management Committee of Changshu New Materials Industrial Park, and Dr. Zhang Jiangang, General Manager of Suzhou yumed Pharmaceutical Technology Co., Ltd., signed a new drug CDMO project on-site. Suzhou yumed Pharmaceutical plans to establish a production base for new raw materials/intermediates in Changshu New Materials Industrial Park, with a total investment of 350 million yuan and a total land area of 55 acres. It mainly engages in integrated services for new drug research and development and production. It is expected that the project will achieve an annual output value of 500 million yuan after completion.